Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

MicuRx Approved for China Launch of Next-Gen Antibiotic

publication date: Jun 4, 2021

MicuRx Pharma was approved for China commercialization of contezolid, its next-gen oxazolidinone antibiotic, to treat complicated skin and soft tissue infection. MicuRx has completed nine contezolid clinical trials both in and outside of China showing efficacy in treating infections caused by multi-drug resistant gram-positive bacteria, while reducing the myelosuppression side effects or inducing drug resistance. Initially, MicuRx will launch contezolid in China while it conducts additional trials in the US. It will be the first MicuRx product to be commercialized. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital